Respiratory Syncytial Virus Prophylaxis in a High-Risk Population in Argentina: A Cost-Effectiveness Analysis

Palivizumab has proved effective in reducing hospitalization rates because of respiratory syncytial virus in vulnerable groups. In Argentina its administration is not universal because of high costs. We made a cohort study and enrolled 159 children who met the American Academy of Pediatrics recommen...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The Pediatric infectious disease journal 2008-07, Vol.27 (7), p.660-661
Hauptverfasser:	Rodríguez, Susana P, Fariña, Diana, Bauer, Gabriela
Format:	Artikel
Sprache:	eng
Schlagworte:	Antibodies, Monoclonal - administration & dosage Antibodies, Monoclonal - pharmacology Antibodies, Monoclonal, Humanized Antiviral Agents - administration & dosage Antiviral Agents - pharmacology Argentina Biological and medical sciences Chemoprevention - economics Chemoprevention - methods Cost-Benefit Analysis General aspects Hospitalization - economics Human viral diseases Humans Immunomodulators Infant Infectious diseases Medical sciences Palivizumab Pharmacology. Drug treatments Respiratory Syncytial Virus Infections - economics Respiratory Syncytial Virus Infections - prevention & control Viral diseases Viral diseases of the respiratory system and ent viral diseases
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!